



20 March 2024

Shareholder Update

1

The American Diabetes Association® (ADA) invites Myopharm to profile pioneering work on TriGlytza™

The American Diabetes Association® (ADA) have invited Myopharm to feature TriGlytza™ in the Thought Leadership Film Series - an exciting element of the 84th Scientific Sessions in Orlando, FL this June.

The ADA are interested in profiling pioneering work on TriGlytza™ that looks to revolutionize the treatment landscape for Type 2 diabetes. Despite the extensive array of treatments currently available, none specifically address the root cause of the disease with a focus on preserving and enhancing the function of pancreatic beta cells, a critical unmet need in the diabetic community.

The ADA, are especially looking to highlight innovative approaches to diabetes management that solve this unmet need because they offer a glimpse into the future of treatment paradigms that are not just palliative but potentially restorative. Given TriGlytza™ introduces a novel 'Beta-cell centric' therapeutic strategy, aiming to maintain or restore beta-cell function while mitigating insulin resistance, they believe our work has the potential to make an incredibly valuable addition to feature in their Thought Leadership Film Series.

Video programs (known as ADA TV) are shown throughout the ADA's Scientific Sessions - the largest diabetes meeting in the world, bringing together industry leaders, government organisations, clinicians, researchers, and other professionals with an interest in diabetes. These videos provide highlights of the Scientific Sessions and feature experts and sponsors sharing details on various topics.

The highlight of the broadcast is the Thought Leadership Film Series. This is an exclusive number of pre-recorded films profiling partners at the forefront of research and innovation across the field. The venture serves to raise the international visibility of those striving to prevent and cure diabetes and to improve the lives of all people affected by the disease.

Myopharm Executive Chair & Chief Executive Officer Karinza Phoenix said "We are extremely proud to be selected for participation in the ADA Scientific Sessions. It validates the importance of the pioneering work of our scientists over many years on TriGlytza™ and we look forward to Myopharm to be showcased at the biggest diabetes meeting in the world."

Karinza Phoenix

Myopharm Limited

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Release authorised by the Executive Chair and Chief Executive Officer of Myopharm Limited

For Investor Enquiries, please get in touch with us at Investor@myopharm.com.

About Myopharm

Website: www.myopharm.com

Myopharm is a diabetes focused company developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our aim is to reduce metabolic diseases that millions of people worldwide are at risk of.

International Diabetes Federation released an alarming growth rate in the prevalence of diabetes, with over 546 million adults worldwide living with diabetes. Closer to home, diabetes is now the fastest-growing chronic condition in Australia.